Stephen B. Gordon

Stephen B. Gordon

Auto-generated profile, based on publicly available information

Stephen B. Gordon

Affiliations Malawi- Liverpool Wellcome Programme, Blantyre, Malawi, Centre for Inflammation Research, University of Edinburgh, Edinburgh, United Kingdom

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2014 in The Lancet Respiratory Medicine
Verified
Journal Article
Closed access
SGStephen B Gordon
Stephen B Gordon
NBNigel G Bruce
Nigel G Bruce
JGJonathan Grigg
Jonathan Grigg
PHPatricia L Hibberd
Patricia L Hibberd
OKOm P Kurmi
Om P Kurmi
WMWilliam J Martin
William J Martin

25 March 2012 in Nature
Verified
Journal Article
Open access
PDF file
TIThe GenISIS Investigators
The GenISIS Investigators
AEAaron R. Everitt
Aaron R. Everitt
MSMalcolm Gracie Semple
Malcolm Gracie Semple
SCSimon Clare
Simon Clare
TPThomas Pertel
Thomas Pertel
PKPaul Kellam
Paul Kellam
Interferon-inducible transmembrane (IFITM) protein 3 is shown to be an innate defence mechanism against viral infection in vivo; furthermore, a subset of the patients hospitalized during the H1N1 2009 pandemic carried a variant form of the IFITM3 gene. Interferon-inducible transmembrane (IFITM) proteins restrict the replication of certain pathogenic viruses, but no in vivo role for these proteins has been known until now. Paul Kellam and colleagues now report that IFITM3 is essential for protecting mice infected with influenza viruses from developing fulminant viral pneumonia. The authors further find that a small subset of humans hospitalized for infection with pandemic H1N1/09 swine flu or seasonal influenza virus carried a variant of IFITM3 with reduced antiviral activity. These results suggest that IFITM3 has a pivotal role in defence against influenza infection. The 2009 H1N1 influenza pandemic showed the speed with which a novel respiratory virus can spread and the ability of a generally mild infection to induce severe morbidity and mortality in a subset of the population. Recent in vitro studies show that the interferon-inducible transmembrane (IFITM) protein family members potently restrict the replication of multiple pathogenic viruses1,2,3,4,5,6,7. Both the magnitude and breadth of the IFITM proteins’ in vitro effects suggest that they are critical for intrinsic resistance to such viruses, including influenza viruses. Using a knockout mouse model8, we now test this hypothesis directly and find that IFITM3 is essential for defending the host against influenza A virus in vivo. Mice lacking Ifitm3 display fulminant viral pneumonia when challenged with a normally low-pathogenicity influenza virus, mirroring the destruction inflicted by the highly pathogenic 1918 ‘Spanish’ influenza9,10. Similar increased viral replication is seen in vitro, with protection rescued by the re-introduction of Ifitm3. To test the role of IFITM3 in human influenza virus infection, we assessed the IFITM3 alleles of individuals hospitalized with seasonal or pandemic influenza H1N1/09 viruses. We find that a statistically significant number of hospitalized subjects show enrichment for a minor IFITM3 allele (SNP rs12252-C) that alters a splice acceptor site, and functional assays show the minor CC genotype IFITM3 has reduced influenza virus restriction in vitro. Together these data reveal that the action of a single intrinsic immune effector, IFITM3, profoundly alters the course of influenza virus infection in mouse and humans.

1 September 2008 in Transactions of the Royal Society of Tropical Medicine and Hygiene
Verified
Journal Article
Open access
DFDuncan G. Fullerton
Duncan G. Fullerton
NBNigel Bruce
Nigel Bruce
SGStephen B. Gordon
Stephen B. Gordon
One-third of the world's population burn organic material such as wood, dung or charcoal (biomass fuel) for cooking, heating and lighting. This form of energy usage is associated with high levels of indoor air pollution and an increase in the incidence of respiratory infections, including pneumonia, tuberculosis and chronic obstructive pulmonary disease, low birthweight, cataracts, cardiovascular events and all-cause mortality both in adults and children. The mechanisms behind these associations are not fully understood. This review summarises the available information on biomass fuel use and health, highlighting the current gaps in knowledge.

4 March 2010 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
NFNeil French
Neil French
SGStephen B. Gordon
Stephen B. Gordon
TMThandie Mwalukomo
Thandie Mwalukomo
SWSarah A. White
Sarah A. White
GMGershom Mwafulirwa
Gershom Mwafulirwa
CGCharles Gilks
Charles Gilks
Streptococcus pneumoniae is a leading and serious coinfection in adults with human immunodeficiency virus (HIV) infection, particularly in Africa. Prevention of this disease by vaccination with the current 23-valent polysaccharide vaccine is suboptimal. Protein conjugate vaccines offer a further option for protection, but data on their clinical efficacy in adults are needed. In this double-blind, randomized, placebo-controlled clinical efficacy trial, we studied the efficacy of a 7-valent conjugate pneumococcal vaccine in predominantly HIV-infected Malawian adolescents and adults who had recovered from documented invasive pneumococcal disease. Two doses of vaccine were given 4 weeks apart. The primary end point was a further episode of pneumococcal infection caused by vaccine serotypes or serotype 6A. From February 2003 through October 2007, we followed 496 patients (of whom 44% were male and 88% were HIV-seropositive) for 798 person-years of observation. There were 67 episodes of pneumococcal disease in 52 patients, all in the HIV-infected subgroup. In 24 patients, there were 19 episodes that were caused by vaccine serotypes and 5 episodes that were caused by the 6A serotype. Of these episodes, 5 occurred in the vaccine group and 19 in the placebo group, for a vaccine efficacy of 74% (95% confidence interval [CI], 30 to 90). There were 73 deaths from any cause in the vaccine group and 63 in the placebo group (hazard ratio in the vaccine group, 1.18; 95% CI, 0.84 to 1.66). The number of serious adverse events within 14 days after vaccination was significantly lower in the vaccine group than in the placebo group (3 vs. 17, P=0.002), and the number of minor adverse events was significantly higher in the vaccine group (41 vs. 13, P=0.003). The 7-valent pneumococcal conjugate vaccine protected HIV-infected adults from recurrent pneumococcal infection caused by vaccine serotypes or serotype 6A. (Current Controlled Trials number, ISRCTN54494731.)

1 January 2017 in The Lancet
Verified
Journal Article
Open access
KMKevin Mortimer
Kevin Mortimer
CNChifundo B Ndamala
Chifundo B Ndamala
ANAndrew W Naunje
Andrew W Naunje
JMJullita Malava
Jullita Malava
CKCynthia Katundu
Cynthia Katundu
SGStephen B Gordon
Stephen B Gordon
WHO estimates exposure to air pollution from cooking with solid fuels is associated with over 4 million premature deaths worldwide every year including half a million children under the age of 5 years from pneumonia. We hypothesised that replacing open fires with cleaner burning biomass-fuelled cookstoves would reduce pneumonia incidence in young children. We did a community-level open cluster randomised controlled trial to compare the effects of a cleaner burning biomass-fuelled cookstove intervention to continuation of open fire cooking on pneumonia in children living in two rural districts, Chikhwawa and Karonga, of Malawi. Clusters were randomly allocated to intervention and control groups using a computer-generated randomisation schedule with stratification by site, distance from health centre, and size of cluster. Within clusters, households with a child under the age of 4·5 years were eligible. Intervention households received two biomass-fuelled cookstoves and a solar panel. The primary outcome was WHO Integrated Management of Childhood Illness (IMCI)-defined pneumonia episodes in children under 5 years of age. Efficacy and safety analyses were by intention to treat. The trial is registered with ISRCTN, number ISRCTN59448623. We enrolled 10 750 children from 8626 households across 150 clusters between Dec 9, 2013, and Feb 28, 2016. 10 543 children from 8470 households contributed 15 991 child-years of follow-up data to the intention-to-treat analysis. The IMCI pneumonia incidence rate in the intervention group was 15·76 (95% CI 14·89-16·63) per 100 child-years and in the control group 15·58 (95% CI 14·72-16·45) per 100 child-years, with an intervention versus control incidence rate ratio (IRR) of 1·01 (95% CI 0·91-1·13; p=0·80). Cooking-related serious adverse events (burns) were seen in 19 children; nine in the intervention and ten (one death) in the control group (IRR 0·91 [95% CI 0·37-2·23]; p=0·83). We found no evidence that an intervention comprising cleaner burning biomass-fuelled cookstoves reduced the risk of pneumonia in young children in rural Malawi. Effective strategies to reduce the adverse health effects of household air pollution are needed. Medical Research Council, UK Department for International Development, and Wellcome Trust.

1 December 2014 in The Lancet
Verified
Journal Article
Closed access
RRRobert C Read
Robert C Read
DBDavid Baxter
David Baxter
DCDavid R Chadwick
David R Chadwick
SFSaul N. Faust
Saul N. Faust
AFAdam Finn
Adam Finn
RBRay Borrow
Ray Borrow